

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>OSPREY MEDICAL INC.</b>
<b>ABN</b>	<b>ARBN 152 854 923</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Erb
<b>Date of last notice</b>	27 May 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct	
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A	
<b>Date of change</b>	8 January 2021	
<b>No. of securities held prior to change</b>	5,000	Options (OSPAO) with exercise price of US\$0.50 per Share
	73,839	Options (OSPAO) with exercise price of US\$0.25 per Share
	178,000	Options (OSPAO) with exercise price of A\$0.38 per Share
	80,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	460,000	Options (OSPAO) with exercise price of A\$0.23 per Share
	Total: <u>796,839</u> Options (OSPAO) (exercisable into an equivalent of 1,593,678 CDIs)	
<b>Class Issued</b>	Options over Shares (not quoted)	

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities issued</b>	626,568 Options (exercisable into an equivalent of 1,253,136 CDIs)	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	In accordance with Osprey's cost reduction initiatives introduced in early 2020 and the Option terms approved by stockholders on 19 June 2020, unlisted Options have been granted to Mr Erb in lieu of directors' fees of US\$21,250 for the period 1 October 2020 to 31 December 2020. The calculation for the number of Options issued was based upon the closing price of the Company's CDIs trading on ASX on 31 December 2020.	
<b>No. of securities disposed/cancelled</b>	Nil	
<b>No. of securities held after change</b>	5,000	Options (OSPAO) with exercise price of US\$0.50 per Share
	73,839	Options (OSPAO) with exercise price of US\$0.25 per Share
	178,000	Options (OSPAO) with exercise price of A\$0.38 per Share
	80,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	460,000	Options (OSPAO) with exercise price of A\$0.23 per Share
	626,568	Options with an exercise price of A\$0.05 per Share
	Total: <u>1,423,407</u> Options (OSPAO) (exercisable into an equivalent of 2,846,814 CDIs)	
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Options pursuant to stockholder approval granted at the Annual Meeting of Stockholders held on 19 June 2020. The exercise price of the Options upon vesting is \$0.05.	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.